Pfizer PFE Earnings Analysis

Earnings Analysis for PFE

Revenue Analysis:

Over the reviewed period, PFE experienced fluctuations in Total and Operating Revenues. Q1 2023 showed the highest revenue at $18.282 billion, which gradually decreased over the subsequent quarters to $14.249 billion by Q4 2023. Similarly, Gross Profit peaked in Q1 2023 at $13.396 billion, reflecting possibly the best operational efficiency within the period, despite Gross Profit margins dropping towards the end of 2023 to $6.686 billion in Q4 2023.

Cost Management:

Cost management remained a challenge, with Costs of Revenue escalating from $4.886 billion in Q1 to $7.563 billion by Q4 2023. Operating Expenses also saw a peak of $8.657 billion in Q4 2023, up from $7.026 billion in Q1 2023. Total Expenses mirrored this trend, escalating from approximately $11.912 billion in Q1 to over $16.22 billion by Q4 2023.

Profitability Analysis:

EBITDA moved from a robust $8.075 billion in Q1 to a negative $1.771 billion by Q4 2023, underscoring a significant profitability squeeze. Likewise, Operating Income deteriorated rapidly from $6.37 billion in Q1 to a loss of $1.971 billion by Q4 2023. Net Income followed this downward trajectory, from a healthy $5.543 billion in Q1 to a substantial loss of $3.369 billion by the end of 2023.

Cash Flow Indicators:

Reconciled Depreciation remained relatively stable, ranging from $1.487 billion in Q1 to $1.67 billion in Q4 2023. Interest Expenses increased over the year, starting at $318 million in Q1 and ending at $688 million in Q4, indicating higher debt service costs.

Taxation:

The effective Tax Rate varied throughout the period, ebbing from 11.4% in Q1 to 19.2% in Q4 2023. Tax Provisions turned negative in Q4 2023 at $-795 million, compared to a positive $715 million in Q1, reflecting the adverse financial results.

Shareholder Metrics:

Basic and Diluted EPS took a hit, turning from a positive $0.98 and $0.97 respectively in Q1 to both hitting -$0.6 by Q4 2023. Average shares stood stable around 5.64 billion, with Net Income to Common Stockholders swinging from plus $5.543 billion in Q1 to minus $3.369 billion by Q4 2023.

Conclusion:

PFE’s financial performance deteriorated significantly through 2023, facing declining revenues, escalating costs, and mounting losses. The increasing operational costs and rising interest expenses ate into profitability, transitioning from a robust profit scenario in Q1 to substantial losses by year’s end. This trend calls for urgent strategic reviews in cost management and operational efficiency to safeguard shareholder value.